Trial Profile
Association between Immune-related adverse events (irAEs) and Clinical outcomes of Nivolumab treatment in patients with Advanced Non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Mar 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2019 Results evaluating nivolumab efficacy according to the development of irAEs, published in the Journal of Cancer Research and Clinical Oncology.
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer